Back to Authors

Vucicevic, Darko

Mayo Clinic

Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona.

Citations 2

Single‐center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area
Lohrmann, Graham , Vucicevic, D., Lawrence, Romy, Steidley, D. Eric , Scott, Robert L. , Kusne, Shimon , Blair, Janis E. , Lohrmann, Graham M, Vucicevic, Darko

Transplant Infectious Disease | July 11, 2017 | Volume: 19 | Issue: 5 | Pages: No page available

10.1111/tid.12744 Get It

AbstractIn endemic regions, coccidioidomycosis causes substantial morbidity and mortality for patients receiving solid organ transplants. We aimed to demonstrate the effect of antifungal coccidioidal prophylaxis in heart transplant (HT) recipients. We retrospectively reviewed the electronic health records of all patients who received HTs between October 19, 2005, and December 13, 2014. We collected information regarding antifungal regimens and determined whether patients subsequently developed infections. Our 174‐person cohort all received antifungal prophylaxis for at least 6 months (mean follow‐up, 53.8 months). One proven and one probable coccidioidal infection (each, 0.6%) occurred during the study period. The incidence of coccidioidomycosis was 0.6% at 1 year and 2.3% at 5 years. No cases of proven coccidioidomycosis occurred within 2 years after transplantation. No patients developed disseminated disease, and no sentinel events were attributed to coccidioidomycosis. Both fluconazole and voriconazole were well tolerated. In the absence of intolerance or contraindication, we suggest continuing a universal antifungal prophylactic regimen with fluconazole for at least 6‐12 months in HT recipients residing in a coccidioidomycosis‐endemic area.
The Incremental Value of Magnetic Resonance Imaging for Identification of Apical Pouch in Patients with Apical Variant of Hypertrophic Cardiomyopathy
Vucicevic, D., Lester, Steven J., Appleton, Christopher P., Panse, Prasad M., Schleifer, J. William , Wilansky, Susan , Vucicevic, Darko, Schleifer, John William

Echocardiography | December 1, 2015 | Volume: 33 | Issue: 4 | Pages: 572-578

10.1111/echo.13118 Get It

BackgroundThe development of a left ventricular (LV) apical pouch in patients with apical hypertrophic cardiomyopathy (aHCM) has been thought to be the transition point that can become an apical aneurysm, which is linked to higher risk of adverse events. In our study, we sought to compare the ability of transthoracic echocardiography (echo) and cardiac magnetic resonance imaging (cMRI) to accurately identify the presence of an apical pouch or aneurysm in patients with aHCM.MethodsWe retrospectively reviewed the charts of all consecutive patients that had features of aHCM on imaging. Data from cMRI and echo examinations were abstracted, and the ability of these diagnostic modalities to identify the presence of a LV apical pouch and aneurysm was analyzed.ResultsOf 31 patients with aHCM, 17 (54.8%) had an apical pouch and 2 were found to have apical aneurysm (6.5%) on cMRI. Echo with and without perflutren contrast was able to accurately identify both aneurysms, but only 47.1% (8/17) of apical pouches seen by cMRI. Two patients had apical thrombus that was identified by cMRI, but not by echo.ConclusionOur findings indicate that cMRI is superior to echo in identifying apical pouches in patients with aHCM. Our results also suggest that in patients undergoing echo, the use of perflutren contrast for LV opacification increases the diagnostic yield. Further study is necessary to delineate whether earlier identification of an apical pouch will be of clinical benefit for patients with aHCM by altering clinical management and avoiding adverse cardiovascular events.